Opioid Use Disorder Market Size & Growth Forecast 2027–2036, By Segments (Route of Administration, Distribution Channel, Drug), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Opioid Use Disorder Market size stood at USD 6.8 billion in 2026 and is predicted to grow at a 9.03% CAGR from 2027 to 2036, attaining USD 16.14 billion by 2036. The industry revenue for 2027 is assessed at USD 7.32 billion.
Get more details on this report
Request Free Sample ReportOpioid Use Disorder Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 66.91% share in 2026, supported by mature treatment infrastructure, medication-assisted treatment availability, and established reimbursement pathways.
- Europe is projected to grow at a 12.32% CAGR, driven by structured treatment models, wider evidence-based care access, and integration of therapy with rehabilitation services.
Segment Momentum
- Injectable Administration held a 62.22% market share in 2026 because long-acting dosing supports treatment adherence, consistent administration, and supervised care, making it well suited for structured clinical management and treatment continuity.
- Retail Pharmacies are expanding rapidly as ongoing treatment increasingly shifts to community settings. Their convenience, wider reach, and easier refill access support routine outpatient medication management and continued therapy.
Market Expansion Drivers
- Rising prevalence of substance use disorders increasing demand for medication-assisted treatment solutions.
- Expanding government funding and public health initiatives improving access to addiction treatment services.
- Growing integration of opioid treatment programs into primary care settings expanding patient outreach.
Leading Market Participants
- Major players in the opioid use disorder market include Indivior PLC (United Kingdom), Teva Pharmaceutical Industries Ltd. (Israel), Collegium Pharmaceutical, Inc. (USA), Alkermes plc (Ireland), Orexo AB (Sweden), Camurus AB (Sweden), Hikma Pharmaceuticals PLC (Jordan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 6.8 billion
- 2027 Estimated Market Size: USD 7.32 billion.
- Projected Market Size: USD 16.14 billion by 2036
- Growth Forecast: 9.03% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Europe
- Core Revenue Segment: Injectable Administration (Route of Administration) | Hospital Pharmacies (Distribution Channel) | Buprenorphine (Drug)
- Emerging Opportunity Segment: Injectable Administration (Route of Administration) | Retail Pharmacies (Distribution Channel) | Buprenorphine (Drug)
Market Growth Drivers and Industry Trends
Rising prevalence of substance use disorders increasing demand for medication-assisted treatment solutions
The growing prevalence of opioid dependence and related substance use disorders is increasing the need for evidence-based treatment approaches, which will drive the opioid use disorder market growth. Medication-assisted treatment can help manage withdrawal symptoms, reduce cravings, and support recovery by combining pharmacological therapy with appropriate behavioral or psychosocial interventions. As healthcare providers encounter more patients requiring structured support for opioid dependence, demand is increasing for treatment solutions that can be incorporated into comprehensive addiction care. Greater recognition of opioid use disorder as a condition requiring sustained medical management is also encouraging broader utilization of established medication-based therapies.
Expanding government funding and public health initiatives improving access to addiction treatment services
Public-sector investment in addiction care is helping reduce barriers to treatment and will propel the opioid use disorder market growth by supporting the expansion of prevention, diagnosis, medication access, and recovery services. Government funding can strengthen treatment infrastructure, improve availability of specialized services, and support programs designed to reach individuals who may otherwise remain outside the healthcare system. Public health initiatives can also promote awareness of opioid dependence and encourage individuals and families to seek professional assistance rather than delaying treatment. Increased institutional attention to addiction as a public health priority is supporting wider implementation of treatment services across communities.
Growing integration of opioid treatment programs into primary care settings expanding patient outreach
Embedding opioid use disorder treatment within primary healthcare is improving opportunities to identify affected individuals and connect them with appropriate care, strengthening the opioid use disorder market. Primary care providers frequently interact with patients who may have untreated or unrecognized substance use problems, creating opportunities for earlier screening, treatment initiation, medication management, and referral to specialized services when required. Integrating addiction treatment into routine healthcare can also reduce the access barriers associated with seeking care exclusively through specialized treatment centers and support continuity for patients with ongoing medical needs. This model enables opioid-related care to become part of broader healthcare management, allowing treatment services to reach patients across more routine points of contact.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of substance use disorders increasing demand for medication-assisted treatment solutions | 2.00% | High | North America, Europe | High | Near Term |
| Expanding government funding and public health initiatives improving access to addiction treatment services | 1.90% | High | North America | High | Near Term |
| Growing integration of opioid treatment programs into primary care settings expanding patient outreach | 1.40% | Moderate | North America, Asia Pacific | Emerging | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
In the opioid use disorder market, North America held the largest share at 66.91% in 2026, underpinned by the substantial clinical and public-health focus on opioid dependence and the expansion of treatment infrastructure. The region has developed extensive networks for medication-assisted treatment, behavioral health services, addiction care, and harm-reduction programs, while heightened awareness of opioid-related risks continues to support demand for diagnosis and long-term treatment. Greater integration of addiction services into mainstream healthcare and ongoing efforts to improve treatment access are reinforcing the region's established market position.
Europe (Fastest-Growing Region)
Europe is witnessing the fastest growth in the opioid use disorder market as healthcare systems place greater emphasis on expanding addiction treatment, improving early intervention, and reducing barriers to care. Increasing recognition of opioid dependence as a complex health condition is encouraging broader adoption of evidence-based treatment approaches and stronger coordination between primary care, mental health services, and specialized addiction programs. Public-health initiatives, efforts to reduce treatment stigma, and improvements in access to medication-based therapies are further supporting the development of the regional market.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Structured rehabilitation pathwaysGermany’s opioid use disorder market is supported by structured rehabilitation and substitution therapy programs within regulated healthcare settings. Providers in Germany focus on coordinated treatment models that combine pharmacological and psychosocial support services.
France 🇫🇷
Public healthcare interventionFrance’s opioid use disorder market is supported by public healthcare-driven intervention programs and harm reduction strategies. In France, treatment systems emphasize accessibility to substitution therapies and long-term patient support frameworks.
Italy 🇮🇹
Community care coordinationItaly’s opioid use disorder market is shaped by community-based care coordination and rehabilitation services delivered through regional health systems. Providers in Italy focus on improving treatment continuity between hospital care and outpatient support networks.
Japan 🇯🇵
Controlled clinical managementJapan’s opioid use disorder market is characterized by tightly regulated clinical management and hospital-based treatment frameworks. In Japan, healthcare providers emphasize controlled therapeutic protocols and careful patient monitoring within specialist care environments.
South Korea 🇰🇷
Clinical treatment integrationSouth Korea’s opioid use disorder market is evolving with increased integration of addiction treatment into mainstream clinical services. Hospitals in South Korea are focusing on multidisciplinary care approaches combining psychiatry, counseling, and pharmacotherapy.
United States 🇺🇸
Treatment access expansionIn the U.S., opioid use disorder treatment is increasingly centered on expanding access to medication-assisted therapies and integrated care programs. Healthcare systems prioritize continuity of care, with strong emphasis on outpatient treatment pathways and behavioral health integration.
Segment Leadership and Growth Trends
Opioid Use Disorder Market Share (%), by Route of Administration, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportRoute of Administration Segment Analysis: Injectable Administration (Largest & Fastest-Growing Segment)
Injectable administration dominated the opioid use disorder market with a 62.22% share in 2026 and is also the fastest-growing route of administration. Its strong position is supported by the ability to provide controlled and sustained delivery of treatments, which can help address adherence challenges associated with opioid use disorder management. Injectable therapies can reduce the need for frequent medication administration and support consistent treatment exposure under clinical supervision. Growing emphasis on treatment continuity, adherence, and structured approaches to addiction care is strengthening the role of injectable administration across opioid use disorder treatment settings.
Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Retail Pharmacies (Fastest-Growing Segment)
Hospital pharmacies accounted for the largest share of the opioid use disorder market, representing 50.77% in 2026. Their leading position reflects the importance of hospital-based care in initiating and managing treatment for patients with opioid use disorder, particularly when clinical monitoring and coordinated medical support are required. Hospital pharmacies facilitate controlled medication dispensing and close integration with healthcare professionals, supporting appropriate treatment management and continuity of care. The growing focus on structured addiction treatment within healthcare systems continues to reinforce demand through this channel.
Retail pharmacies are emerging as the fastest-growing distribution channel as opioid use disorder treatment increasingly emphasizes accessibility and continuity beyond hospital settings. Their broader geographic availability can make medication access more convenient for patients receiving ongoing therapy, while established pharmacy networks support prescription fulfillment and treatment continuity. Greater integration of addiction treatment into community-based healthcare and increasing attention to convenient medication access are expected to support the expanding role of retail pharmacies.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Route of Administration | Oral Administration, Injectable Administration, Others | Injectable Administration | Injectable Administration |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Others | Hospital Pharmacies | Retail Pharmacies |
| Drug | Naltrexone, Buprenorphine, Methadone, Others | Buprenorphine | Buprenorphine |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Prominent players in the opioid use disorder market:
1. Indivior PLC (United Kingdom)
2. Teva Pharmaceutical Industries Ltd. (Israel)
3. Collegium Pharmaceutical Inc. (USA)
4. Alkermes plc (Ireland)
5. Orexo AB (Sweden)
6. Camurus AB (Sweden)
7. Hikma Pharmaceuticals PLC (Jordan)
Ongoing efforts to improve addiction treatment outcomes are influencing developments in the opioid use disorder market. Industry participants are focusing on long-acting therapies, patient adherence solutions, and integrated behavioral treatment approaches to enhance recovery effectiveness. Regulatory support for expanded treatment accessibility and harm reduction initiatives is also encouraging therapeutic innovation within the sector.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Indivior PLC (United Kingdom) | |||||||
| Teva Pharmaceutical Industries Ltd. (Israel) | |||||||
| Collegium Pharmaceutical Inc. (USA) | |||||||
| Alkermes plc (Ireland) | |||||||
| Orexo AB (Sweden) | |||||||
| Camurus AB (Sweden) | |||||||
| Hikma Pharmaceuticals PLC (Jordan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| U.S. Department of Health and Human Services | Feb-26 | The U.S. Department of Health and Human Services launched the $100 million STREETS Initiative to strengthen the national response to opioid addiction. The federal funding aims to expand evidence-based treatment access, improve clinical recovery support systems, and bolster community-level interventions to reduce mortality rates and enhance the overall continuity of care for affected populations. |
| Be Well Texas | Jul-25 | The Texas Health and Human Services Commission awarded $256 million to Be Well Texas to scale opioid use disorder treatment services statewide. This major investment focuses on expanding access to medications such as naloxone, enhancing recovery support infrastructure, and strengthening addiction care delivery networks to serve both rural and urban populations more effectively. |
| Acadia Healthcare | Oct-24 | Acadia Healthcare acquired three behavioral health facilities to expand its operational footprint in the addiction treatment sector. This acquisition supports the company’s geographic expansion strategy and integrates additional capacity for delivering medication-assisted treatment and comprehensive behavioral health services, reinforcing its market position as a key provider of integrated addiction recovery programs. |
| Cedar Recovery | Jul-24 | Cedar Recovery launched CedarRx, an on-site pharmacy model designed to centralize access to addiction treatment medications. This initiative streamlines medication-assisted treatment delivery, reduces logistical barriers for patients, and enhances treatment adherence by integrating pharmacy services directly within the clinical care setting to ensure greater continuity of care. |
| Highmark Wholecare; Ophelia | Apr-24 | Highmark Wholecare and Ophelia formed a partnership to address treatment access gaps for Medicaid enrollees. By integrating payer support with a digital-first addiction treatment platform, the collaboration aims to improve entry into medication-assisted treatment programs, enhance care coordination, and reduce health disparities to drive better patient engagement and long-term recovery outcomes. |
| Titan Pharmaceuticals, Inc. | Jul-23 | Titan Pharmaceuticals entered into an asset purchase agreement with Fedson, Inc. to divest its ProNeura technology assets. This sale included its portfolio of addiction treatment medications and early-stage drug delivery projects, specifically impacting the development programs for Nalmefene and Probuphine implants, marking a strategic shift in the company’s focus. |
| Indivior PLC | Mar-23 | Indivior PLC completed the strategic acquisition of Opiant Pharmaceuticals, Inc. to enhance its portfolio of opioid addiction and overdose treatment solutions. This transaction significantly strengthens Indivior's competitive positioning and expands its pipeline of therapeutic assets aimed at addressing the critical requirements for effective opioid use disorder management. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Opioid Use Disorder Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Treatment Stage | Induction/Initiation, Stabilization, Maintenance, Recovery/Discontinuation |
| Payer Type | Public Payers, Private/Commercial Payers, Self-Pay/Uninsured |
| Patient Population | Adults, Adolescents, Pregnant Patients, Older Adults |
Opioid Use Disorder Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Treatment Access and Care Delivery Landscape |
|
| Medication-Assisted Treatment Adoption Benchmark |
|
| Payer Coverage and Reimbursement Opportunity Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow big is the opioid use disorder market?
How is the opioid use disorder industry expected to grow over the next 10 years?
How is expanded access to addiction treatment reshaping adoption patterns in the opioid use disorder market?
How is integration of opioid treatment into primary care influencing market growth strategies?
Why is Injectable Administration the leading route of administration in the opioid use disorder market?
Why are Retail Pharmacies the fastest-growing distribution channel in the opioid use disorder market?
Why does North America lead the opioid use disorder market?
How is Europe emerging as a growth region in opioid use disorder care?
Who are the major participants shaping the opioid use disorder landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization